Neuroblastoma Market Trends

ID: MRFR/HC/5093-HCR

200 Pages

Rahul Gotadki

October 2025

Neuroblastoma Market Research Report By Treatment Type (Chemotherapy, Surgery, Radiation Therapy, Immunotherapy), By End-user (Hospitals, Specialized Cancer Treatment Centers, Research Institutions), By Disease Stage (Localized Neuroblastoma, Metastatic Neuroblastoma, Recurrent Neuroblastoma), By Age Group (Infants, Children, Adolescents), and By Regional (North America, Europe, South America, Asia Pacific, Middle East and Africa) - Forecast to 2035

Request Free Sample

Summary Table of Contents Segmentation Download PDF

Market Trends

Key Emerging Trends in the Neuroblastoma Market

The Neuroblastoma market has witnessed significant trends, reflecting the advancements in research, diagnostics, and treatment options for this pediatric cancer. Neuroblastoma is a type of cancer that primarily affects children and arises from immature nerve cells. One notable trend is the increasing emphasis on precision medicine in the treatment of neuroblastoma. Advances in genomic profiling and molecular diagnostics have enabled healthcare professionals to identify specific genetic markers associated with neuroblastoma, paving the way for targeted therapies tailored to the individual genetic makeup of the tumor. This trend is crucial in improving treatment outcomes and minimizing the side effects of interventions for pediatric patients.

Furthermore, the market is experiencing a surge in research and development activities focused on novel therapies for neuroblastoma. The exploration of immunotherapies, including monoclonal antibodies and immune checkpoint inhibitors, has shown promise in enhancing the body's ability to recognize and eliminate cancer cells. Additionally, advancements in the development of targeted small molecule inhibitors and novel chemotherapy agents are contributing to a more diversified and effective therapeutic arsenal against neuroblastoma. The ongoing research efforts aim to improve the overall survival rates and reduce the long-term adverse effects associated with current treatment modalities.

Technological advancements in diagnostic tools and imaging techniques are playing a pivotal role in shaping market trends within the neuroblastoma space. Innovations in molecular imaging, positron emission tomography (PET), and magnetic resonance imaging (MRI) are enhancing the accuracy of neuroblastoma diagnosis and staging. Early and precise detection of the disease is crucial for determining the appropriate treatment strategies and improving patient outcomes. The integration of advanced imaging technologies is contributing to more effective risk stratification and personalized treatment planning for children with neuroblastoma.

Another significant trend is the growing awareness and collaboration in the research and advocacy communities dedicated to neuroblastoma. The establishment of collaborative research networks, partnerships between academic institutions and pharmaceutical companies, and the involvement of patient advocacy groups are driving concerted efforts to accelerate the development of new therapies and improve the overall care and support for children with neuroblastoma. This trend highlights the recognition of the complexity of neuroblastoma and the need for a multidisciplinary approach to address the challenges associated with its diagnosis and treatment.

The market for neuroblastoma is also witnessing an increased focus on supportive care and survivorship programs. As the survival rates for neuroblastoma improve, there is a growing recognition of the long-term physical and psychological challenges faced by survivors. Supportive care initiatives aim to address the unique needs of neuroblastoma survivors, including monitoring for late effects of treatment, providing psychosocial support, and promoting overall well-being. This trend reflects the commitment to enhancing the quality of life for children who have undergone neuroblastoma treatment.

Geographically, market trends in neuroblastoma vary based on regional healthcare infrastructures, research capabilities, and the prevalence of the disease. Developed regions with advanced healthcare systems are often at the forefront of research and therapeutic advancements, with a focus on implementing cutting-edge diagnostic and treatment modalities. In contrast, emerging regions may face challenges in terms of access to advanced diagnostics and therapies, necessitating collaborative efforts to bridge the gap in neuroblastoma care.

Market Highlights

Author

Rahul Gotadki

Assistant Manager

He holds an experience of about 7+ years in Market Research and Business Consulting, working under the spectrum of Life Sciences and Healthcare domains. Rahul conceptualizes and implements a scalable business strategy and provides strategic leadership to the clients. His expertise lies in market estimation, competitive intelligence, pipeline analysis, customer assessment, etc. In addition to the above, his other responsibility includes strategic tracking of high growth markets & advising clients on the potential areas of focus they could direct their business initiatives

Get In Touch

FAQs

What is the projected growth of the Neuroblastoma market?

The Neuroblastoma market is the expected increase in total market value of 0.56 USD billion over a defined forecast period 2025–2035. It is driven by factors such as demand trends, technological advances, regulatory changes, and geographic expansion.

What is the size of the Neuroblastoma market?

Neuroblastoma market size was valued at approximately 0.39 billion USD in 2024. This figure will reach 0.56 billion USD covering all regions (America, Europe, Asia, MEA and ROW), focusing its segments / services / distribution channels till 2035.

What is the CAGR of the Neuroblastoma market?

Neuroblastoma market is expected to grow at a CAGR of 3.4% between 2025 and 2035.

How much will the Neuroblastoma market be worth by 2035?

Neuroblastoma market is expected to be worth of 0.56 billion USD, reflecting growth driven by usage, technology and global demands by the end of 2035.

How will the Neuroblastoma market perform over the next 10 years?

Over the next 10 years the Neuroblastoma market is expected to shift from usd billion 0.39 to 0.56 billion USD, led by adoption of advanced tech, demographic trends, regulatory approvals, with potential headwinds from 2025 to 2035.

What was the market size of the Neuroblastoma Market in 2024?

The Neuroblastoma Market was valued at 2.4 USD Billion in 2024.

Which region held the largest market share in the Neuroblastoma Market in 2024?

In 2024, North America held the largest market share at 1.3 USD Billion.

What was the market size for Chemotherapy in the Neuroblastoma Market in 2024?

The market size for Chemotherapy in the Neuroblastoma Market was 1.2 USD Billion in 2024.

How much is the Immunotherapy segment expected to be valued in 2035?

The Immunotherapy segment of the Neuroblastoma Market is expected to be valued at 0.1 USD Billion in 2035.

What is the growth rate for the Asia Pacific region from 2024 to 2035?

The Asia Pacific region is expected to grow from 0.3 USD Billion in 2024 to 0.6 USD Billion by 2035.

1. Market Overview

2. Market Trends

3. Market Segment Insights

4. Key Players and Competitive Insights

5. Industry Developments

6. Market Segmentation

7. Report Scope

8. Market Highlights

9. FAQs

Customize Report

Certified Researchers

Market Summary

As per Market Research Future Analysis, the Neuroblastoma Market was valued at 0.39 USD Billion in 2024 and is projected to grow to 0.56 USD Billion by 2035, with a CAGR of 3.40% from 2025 to 2035. The market is driven by increased awareness, advancements in medical technology, and government funding for pediatric cancer therapies. Challenges include the rising prevalence of neuroblastoma in children, necessitating innovative treatment options. The market is characterized by significant growth in treatment modalities such as chemotherapy, surgery, radiation therapy, and immunotherapy, with a focus on personalized medicine and holistic care.

Key Market Trends & Highlights

Key trends driving the Neuroblastoma Market include advancements in treatment modalities and increased awareness.

Neuroblastoma Market Size in 2024: 0.39 USD Billion; expected to reach 0.56 USD Billion by 2035. Chemotherapy valued at 0.9 USD Billion in 2024; projected to grow to 1.7 USD Billion by 2035. North America leads the market with a valuation of 0.847 USD Billion in 2024; expected to grow to 1.592 USD Billion by 2035. Over 50 active clinical trials for neuroblastoma therapies currently in progress.

Market Size & Forecast

2024 Market Size	USD 0.39 Billion
2035 Market Size	USD 0.56 Billion
CAGR (2025-2035)	3.40%
Largest Regional Market Share in 2024	North America.

Major Players

Takeda, Pfizer, Blueprint Medicines, Roche, AbbVie, Eli Lilly, Incyte, Seattle Genetics, Eisai, Novartis, Celgene, Bristol-Myers Squibb, <a href="https://www.merckmanuals.com/professional/pediatrics/pediatric-cancers/neuroblastoma">Merck</a>, AstraZeneca, and Amgen.

Market Trends

Research breakthroughs and growing awareness of pediatric tumors are the primary drivers of the notable trends currently observed in the Neuroblastoma Market. More instances of neuroblastoma are being discovered worldwide as a result of improved early identification made possible by advancements in diagnostic technology.

There are now more therapy alternatives for patients thanks to the increased cooperation between pharmaceutical corporations and research institutes, which has sped up the development of novel medications. Further driving market expansion is the increasing support from governmental and nonprofit institutions, which emphasizes how urgent it is to treat this uncommon cancer.

The development of immunotherapies and tailored medicines, which promise greater efficacy with fewer adverse effects, are opportunities to be investigated in this field. The possibility for developing customized medical solutions tailored to neuroblastoma patients is increasing as research advances, and doing so might greatly enhance treatment results.

Additionally, international initiatives to improve access to specialized treatment and healthcare infrastructure can offer a platform for raising awareness and enhancing patient outcomes. Current patterns indicate a move toward more all-encompassing care regimens that take into account impacted families' psychological needs in addition to medical therapy.

This comprehensive strategy is essential because it recognizes the wide-ranging effects neuroblastoma has on kids and their families.

Supportive services are therefore becoming a more important part of care in the Neuroblastoma Market as medical professionals incorporate them more and more into their treatment plans. The continuous changes in international regulations intended to enhance the treatment of pediatric illnesses also foster an atmosphere that is conducive to market expansion and innovation.

Neuroblastoma Market Market Drivers

Market Growth Projections

The Global Neuroblastoma Market Industry is projected to experience substantial growth over the next decade. By 2024, the market is anticipated to reach 2.4 USD Billion, with expectations to expand to 4.5 USD Billion by 2035. This growth trajectory suggests a compound annual growth rate of 5.88% from 2025 to 2035. Factors contributing to this growth include increasing incidence rates, advancements in treatment modalities, and rising awareness among healthcare professionals and the public. As the market evolves, it is likely to attract further investment and innovation, ultimately benefiting patients and healthcare providers alike.

Rising Awareness and Advocacy

Rising awareness and advocacy efforts surrounding neuroblastoma are pivotal in shaping the Global Neuroblastoma Market Industry. Non-profit organizations and advocacy groups are actively working to educate the public about neuroblastoma, its symptoms, and the importance of early detection. Campaigns aimed at increasing awareness have led to greater funding for research and improved access to treatment options. This heightened awareness is expected to result in an increased diagnosis rate, thereby expanding the market. As more families seek information and support, the demand for comprehensive care solutions is likely to grow, further driving market dynamics.

Enhanced Diagnostic Techniques

Enhanced diagnostic techniques are transforming the landscape of the Global Neuroblastoma Market Industry. Advances in imaging technologies, such as MRI and PET scans, along with genetic testing, are enabling earlier and more accurate diagnosis of neuroblastoma. These innovations facilitate timely intervention, which is crucial for improving patient outcomes. As healthcare providers adopt these advanced diagnostic tools, the market is poised for growth. The increasing emphasis on precision medicine and personalized treatment plans is likely to further propel the demand for diagnostic services, ensuring that patients receive the most effective care tailored to their specific needs.

Advancements in Treatment Modalities

The Global Neuroblastoma Market Industry is significantly influenced by advancements in treatment modalities. Innovative therapies, including targeted therapies and immunotherapy, are emerging as promising options for neuroblastoma patients. For instance, the development of monoclonal antibodies and CAR T-cell therapy has shown potential in improving survival rates. As these treatments gain regulatory approval and clinical adoption, they are likely to drive market growth. The market is expected to reach 4.5 USD Billion by 2035, indicating a robust demand for novel therapeutic approaches that enhance patient outcomes and quality of life.

Increasing Incidence of Neuroblastoma

The Global Neuroblastoma Market Industry is witnessing a rise in the incidence of neuroblastoma, particularly among children under the age of five. This increase is attributed to various factors, including genetic predispositions and environmental influences. The World Health Organization reports that neuroblastoma accounts for approximately 7-10% of all childhood cancers. As awareness grows and diagnostic techniques improve, more cases are being identified, contributing to the market's expansion. In 2024, the market is projected to reach 2.4 USD Billion, reflecting the urgent need for effective treatment options and supportive care for affected families.

Growing Investment in Research and Development

Investment in research and development is a crucial driver for the Global Neuroblastoma Market Industry. Governments and private organizations are increasingly funding research initiatives aimed at understanding the biology of neuroblastoma and developing new treatment strategies. For example, the National Cancer Institute allocates substantial resources to neuroblastoma research, fostering collaborations between academic institutions and pharmaceutical companies. This influx of funding is likely to accelerate the discovery of innovative therapies and diagnostic tools, contributing to a projected compound annual growth rate of 5.88% from 2025 to 2035, thereby enhancing the market's overall landscape.

Market Segment Insights

Neuroblastoma Market Treatment Type Insights

In the Neuroblastoma Market, the treatment type segment played a crucial role, yielding significant revenue and showcasing diverse methodologies adopted to combat this pediatric cancer.

<a href="https://www.marketresearchfuture.com/reports/chemotherapy-market-5791">Chemotherapy</a> held the majority share, with a remarkable valuation of 1.2 USD Billion in 2024 and projected to increase to 2.3 USD Billion by 2035, demonstrating its pivotal role in the treatment protocol for Neuroblastoma Market. This treatment type remained predominant due to its effectiveness in targeting rapidly dividing cancer cells, making it a primary choice for physicians globally.

Surgery, valued at 0.7 USD Billion in 2024 and expected to rise to 1.2 USD Billion in 2035, was also a significant modality, providing a curative approach by physically removing tumor masses.

The importance of surgical intervention cannot be overstated, as it allowed for the resection of neuroblastoma and minimizes further complications or metastasis, hence dominating specific cases where tumors are operable.

Radiation Therapy, contributing 0.5 USD Billion in 2024 with expectations to grow to 0.9 USD Billion by 2035, functions as an adjunctive treatment following surgery or chemotherapy. Its role was crucial in managing residual tumor cells, thereby decreasing the risk of recurrence, which underscored its importance in treatment protocols.

Neuroblastoma Market End-user Insights

The Neuroblastoma Market revenue is showcasing significant growth potential across its diverse End-user landscape, which includes Hospitals, Specialized Cancer Treatment Centers, and Research Institutions. Hospitals play a crucial role in providing immediate care and treatment, catering to a substantial patient base and ensuring accessibility to essential therapies.

Specialized Cancer Treatment Centers are becoming increasingly important, as they focus on advanced treatment options and clinical trials specifically tailored for neuroblastoma, thus driving innovation in care.

Research Institutions are pivotal in spearheading scientific advancements related to this rare pediatric cancer, enabling the development of new therapeutic strategies. The Neuroblastoma Market segmentation reflects the importance of each End-user in the collective effort to address and improve treatment outcomes for patients.

The increasing prevalence of neuroblastoma, coupled with advancements in technology and therapeutic agents, presents ample opportunities for growth in this sector. However, challenges such as funding limitations in research and varying healthcare infrastructure can affect market dynamics.

The significance of these End-users underlines their vital contributions to improving clinical outcomes and advancing the overall understanding of neuroblastoma treatments within the Global context.

Neuroblastoma Market Disease Stage Insights

The segment is a critical aspect, highlighting the different pathological stages that this pediatric cancer can present. Localized Neuroblastoma Market is vital as it currently constitutes a significant portion of diagnoses, displaying better prognoses with high survival rates due to timely treatment.

In contrast, Metastatic Neuroblastoma Market poses considerable challenges; this advanced stage spreads the malignancy and accounts for a higher percentage of treatment difficulties, driving demand for novel therapies and Research and Development initiatives.

Recurrent Neuroblastoma Market, detected after initial treatment, poses a unique set of challenges, with relapses prompting a need for continuous monitoring and advanced treatment strategies. As the market evolves, rising incidences and increasing awareness are propelling growth in the Neuroblastoma Market, indicating robust potential across different stages of the disease.

The market statistics reflect an increasing focus on innovative therapeutic options and the management of these distinct disease stages, making it a subject of research and a priority within the Global healthcare industry.

Neuroblastoma Market Age Group Insights

The Neuroblastoma Market exhibits a robust segmentation by Age Group, primarily encompassing Infants, Children, and Adolescents. Infants represent a critical demographic due to the high incidence of neuroblastoma at this early age, necessitating tailored treatment strategies and early diagnosis initiatives.

The prevalence among Children continues to dominate the market as this group experiences varying forms which require comprehensive management approaches. Furthermore, the Adolescents segment is gaining attention, representing a growing focus on therapies suited to this age range, contributing to a more holistic understanding of the disease.

The Neuroblastoma Market statistics reveal a consistent growth trajectory, driven by advancements in Research and Development, increasing awareness, and support from healthcare systems worldwide. However, challenges such as treatment accessibility and cost-effective solutions persist, prompting opportunities for innovative therapeutic approaches.

The overall dynamics of the Neuroblastoma Market segmentation underscore the importance of a multi-faceted strategy that addresses the unique needs of each age group while fostering market growth and ensuring better outcomes for affected individuals.

Get more detailed insights about Neuroblastoma Market Research Report – Forecast to 2035

Regional Insights

North America led the market with a valuation of 1.3 USD Billion for 2024, and this significant share highlights the region's advanced healthcare infrastructure and research initiatives which drive treatment options.

Europe followed with a market value of 0.6 USD Billion, benefiting from its emphasis on early diagnosis and established treatment protocols, thus making it a key player in the Neuroblastoma Market.

South America and Asia Pacific were valued at 0.2 USD Billion and 0.3 USD Billion, respectively, reflecting a growing awareness and investment in pediatric oncology even though they held smaller percentages of the overall market.

The Middle East and Africa also presented opportunities with a combined value of 0.2 USD Billion. These regions are leveraging international partnerships and support from global organizations to enhance their healthcare frameworks for neuroblastoma treatment.

The market growth across these segments was driven by increasing incidences of neuroblastoma, advancements in treatment modalities, and a push towards improved patient outcomes. The Neuroblastoma Market revenue trends indicated rising investment in Research and Development across all regions, signifying potential for future advancements and refinements in treatment methodologies.

Key Players and Competitive Insights

The Neuroblastoma Market is witnessing significant advancements driven by increasing research funding, heightened awareness of pediatric cancers, and technological innovations in drug development and diagnostic methods. This market primarily focuses on the development of treatments and therapeutics targeting neuroblastoma, a form of cancer that predominantly affects children.

Insights into the competitive landscape reveal a dynamic array of pharmaceutical companies striving to innovate and provide effective therapies. They are engaged in extensive clinical trials, collaborations with research institutions, and strategic partnerships aimed at improving treatment outcomes and extending survival rates for affected patients.

Understanding the competitive dynamics of this market is essential for stakeholders aiming to navigate the challenges and leverage the opportunities that arise from a rapidly evolving therapeutic landscape.

Novartis holds a prominent position in the Neuroblastoma Market, leveraging its robust portfolio and extensive research experience. The company is recognized for its commitment to developing innovative therapies and has established a strong global presence through partnerships and collaborations focusing on pediatric oncology.

Its strengths lie in advanced research capabilities, a well-established pipeline of potential neuroblastoma treatments, and an effective marketing strategy that facilitates product accessibility. Novartis continues to explore new therapeutic avenues and aims to address unmet medical needs through its dedicated focus on this rare cancer type.

The company’s ability to engage with regulatory bodies and foster collaborations ensures that it remains at the forefront of developments in the neuroblastoma therapeutic space.

Black Diamond Therapeutics is another key player within the Neuroblastoma Market, primarily focused on developing allosteric modulators that target specific genetic mutations associated with neuroblastoma. The company has carved a niche in the market with its unique approach to drug discovery and development, working to bring innovative therapies to patients worldwide.

Black Diamond Therapeutics is noted for its strong pipeline which includes various drug candidates specifically designed to address neuroblastoma treatment. The company has established strategic partnerships and collaborations aimed at enhancing its research capabilities and expanding its reach within the global market.

Through mergers, acquisitions, and focused research efforts, Black Diamond Therapeutics is strengthening its position and aims to contribute significantly to improving the lives of patients affected by neuroblastoma. Their commitment to innovation and patient-centric therapies further solidifies their role in this competitive landscape.

Key Companies in the Neuroblastoma Market market include

Industry Developments

The first patient is anticipated to enroll in mid-2025. On June 13, 2025, Myrio Therapeutics announced that the U.S. FDA had approved its Investigational New Drug application for PHOX2B PC-CAR T, a novel CAR-T cell therapy intended to target the PHOX2B peptide in multiple HLA-alleles across pediatric neuroblastoma patients.

Following promising results in two Phase 2 trials showing overall response rates of 34–45% and durable responses lasting six months or longer, the FDA granted accelerated approval to naxitamab (Danyelza) on November 25, 2020, for the treatment of relapsed or refractory high-risk neuroblastoma affecting bone or bone marrow in patients aged one year and older.

Based on data from SIOPEN trials that showed five-year event-free survival rates of 57% versus 42% with standard care, China's National Medical Products Administration granted conditional approval for dinutuximab beta (Qarziba) to treat high-risk neuroblastoma in pediatric patients aged 12 months and older on August 17, 2021.

The New Approaches to Neuroblastoma Market Therapy (NANT) trial's Phase 1 clinical data, released by Panbela Therapeutics on January 18, 2024, demonstrated that a combination of high-dose DFMO, celecoxib, cyclophosphamide, and topotecan offered tolerable safety and possible therapeutic activity in patients with relapsed neuroblastoma who had received extensive pretreatment.

Aptorum Group filed its Phase 1b/2a clinical trial protocol to the FDA on June 22, 2023, for patients with refractory high-risk neuroblastoma or first-relapse. SACT-1 is an oral small chemical that targets MYCN amplification.

Future Outlook

Neuroblastoma Market Future Outlook

The Neuroblastoma Market is projected to grow at a 5.88% CAGR from 2025 to 2035, driven by advancements in targeted therapies and increasing awareness.

New opportunities lie in:

Invest in innovative immunotherapy solutions to enhance treatment efficacy. Develop comprehensive patient support programs to improve treatment adherence. Leverage data analytics for personalized treatment plans and outcomes tracking.

By 2035, the Neuroblastoma Market is expected to exhibit robust growth, reflecting advancements in treatment and increased patient access.

Market Segmentation

Neuroblastoma Market End-user Outlook

Hospitals
Specialized Cancer Treatment Centers
Research Institutions

Neuroblastoma Market Age Group Outlook

Infants
Children
Adolescents

Neuroblastoma Market Disease Stage Outlook

Localized Neuroblastoma Market
Metastatic Neuroblastoma Market
Recurrent Neuroblastoma Market

Neuroblastoma Market Treatment Type Outlook

Chemotherapy
Surgery
Radiation Therapy
Immunotherapy

Report Scope

Report Attribute/Metric	Details
Market Size 2024	2.4(USD Billion)
Market Size 2035	0.56 (USD Billion)
Compound Annual Growth Rate (CAGR)	3.40% (2025 - 2035)
Report Coverage	Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
Base Year	2024
Market Forecast Period	2025 - 2035
Historical Data	2019 - 2024
Market Forecast Units	USD Billion
Key Companies Profiled	Novartis, Black Diamond Therapeutics, Children's Oncology Group, Takeda Pharmaceutical, Pfizer, OncoOne, Merck & Co, AstraZeneca, Amgen, Eli Lilly and Company, Sobi, Johnson & Johnson, Roche, Bristol Myers Squibb, AbbVie
Segments Covered	Treatment Type, End-user, Disease Stage, Age Group, Regional
Key Market Opportunities	Increasing pediatric cancer awareness, Advances in immunotherapy treatments, Expanding clinical trial pipelines, Growing demand for targeted therapies, Rising investments in biotech research
Key Market Dynamics	Increasing incidence rates, Growing research funding, Advancements in treatment modalities, Rising awareness and screening, Strong pipeline of therapies
Countries Covered	North America, Europe, APAC, South America, MEA
Market Size 2025	0.40 (USD Billion)